
The U.S. Food and Drug Administration on Wednesday approved the first fecal microbiota treatment, aimed at helping adults battling tough-to-treat Clostridium difficile (C. diff) infections. “Today’s approval of Rebyota is an advance in caring for patients who have recurrent C. difficile infection [CDI],” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation… read on > read on >